Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 3/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meglumine SCHEMBL1812995 | 0.96 | PTPN11 (0.54) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| SCHEMBL1734725 | 0.87 | PTPN11 (0.71) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| Meglumine SCHEMBL1813196 | 0.87 | PTPN11 (0.75) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| SCHEMBL1734580 | 0.83 | PTPN11 (0.69) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| Meglumine SCHEMBL1814503 | 0.79 | PTPN11 (0.62) | PTPN11PTPROSTAT3KAT8 | |
| SCHEMBL12656084 | 0.79 | STAT3 (0.59) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| SCHEMBL1734858 | 0.78 | PTPN11 (0.60) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| SCHEMBL1734777 | 0.78 | PTPN11 (0.59) | PTPN11PTPROSTAT3LTB4R2LPAR1 | |
| SCHEMBL1810218 | 0.76 | PTPN11 (0.61) | PTPN11PTPROSTAT3KAT8LTB4R2 | |
| SCHEMBL1814985 | 0.76 | PTPN11 (0.59) | PTPN11PTPROSTAT3KAT8LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | PTPN11 38/4885PTPRO 4/4885STAT3 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.